Novo Nordisk announced, liraglutide (Victoza) has been approved for young people with Type 2 diabetes between the ages of 10-17 years old.
The U.S. Food and Drug Administration has approved the medication for children that was previously only approved for adults.
“As the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes, liraglutide (Victoza) provides this population with a new treatment option beyond metformin and insulin for the first time in 19 years.”
With the increasing rates of Type 2 diabetes in children, this offers clinicians a new treatment option outside of metformin and insulin.
“Type 2 diabetes is the most common form of diabetes, normally occurring in people 45 years or older, but its prevalence among the younger population has climbed dramatically over the past 20 years.”
Type 2 diabetes, which was once considered a rare condition in the pediatric population, now accounts for about 15% to 45% of all newly diagnosed cases of diabetes in children and teenagers.
The approval of liraglutide (Victoza) could help considerably with the treatment of Type 2 in children.
Original Article: FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years – Novo Nordisk
Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE! Sign up below!